NCT07463287Recruiting
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 5 Mar 2026
- Start date
- 30 Apr 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Shanghai East Hospital
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07463287
What you commit to
- Study type: Observational
- Planned participants: 100
- From 30 Apr 2025 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer;
- Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders;
Other
- Individuals lacking legal capacity or with poor insight.
Who the study is looking for
- Diagnosis of MAFLD conforms to the "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease" (2018 Edition);
- Male or female patients aged 18-70 years;
- Signed informed consent form and explanation of the specific study protocol.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai East Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.